WANBURY
Back to Balance Sheet
|
WANBURY Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹173 Cr | ₹99 Cr | ₹11 Cr | ₹11 Cr | ₹84 Cr |
What is the latest Total Non-Current Liabilities ratio of WANBURY ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹173 Cr |
| Mar2024 | ₹99 Cr |
| Mar2023 | ₹11 Cr |
| Mar2022 | ₹11 Cr |
| Mar2021 | ₹84 Cr |
How is Total Non-Current Liabilities of WANBURY Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹173 Cr | 74.78 | |
| Mar2024 | ₹99 Cr | 815.56 | |
| Mar2023 | ₹11 Cr | 2.34 | |
| Mar2022 | ₹11 Cr | -87.49 | |
| Mar2021 | ₹84 Cr | - | |
Compare Total Non-Current Liabilities of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹844.6 Cr | -5% | -9% | 15.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,555.0 Cr | -2.2% | 2.5% | 1.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,889.0 Cr | -1.2% | -4.5% | 5.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹144,073.0 Cr | -2.1% | -0.2% | 36.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,133.0 Cr | -2.4% | -2.1% | 11.5% | Stock Analytics | |
| CIPLA | ₹98,492.9 Cr | -4.6% | -8% | -16.8% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -5% |
-9% |
15.2% |
| SENSEX | -2.6% |
-10.2% |
-1.6% |
You may also like the below Video Courses